The 5th International Consensus Conference for Advanced
Breast Cancer (ABC5) took place on November 14–16, 2019,
in Lisbon, Portugal. Its aim is to standardize the treatment of
advanced breast cancer based on the available evidence and
to ensure that all breast cancer patients worldwide receive
adequate treatment and access to new therapies. This year,
the conference focused on developments and study results
in the treatment of patients with hormone receptor-positive/HER2-negative breast cancer as well as precision medicine. As in previous years, patient advocates from around the
world were integrated into the ABC conference and had seats on the ABC consensus panel. In the present paper, a
working group of German breast cancer experts comments
on the results of the on-site ABC5 consensus votes by ABC
panelists regarding their applicability for routine treatment
in Germany. These comments take the recommendations of
the Breast Committee of the Gynecological Oncology Working Group (Arbeitsgemeinschaft Gynäkologische Onkologie;
AGO) into account. The report and assessment presented
here pertain to the preliminary results of the ABC5 consensus. The final version of the statements will be published in
Annals of Oncology and The Breast